Syncom Formulations (India) growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+5.2%+76.6%+17.5%
+43.0%+82.6%+51.0%
+44.9%+96.3%+65.2%
+54.6%+95.3%+26.1%
+42.1%+67.6%+41.7%
+29.2%+2.1%+7.1%
+21.3%+18.7%+12.5%
+147.8%+493.3%−156.6%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNCOMF₹21.20

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,993 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+17.5+76.6+5.2—
EBITDA Growth—+51.0+82.6+43.0—
EBIT Growth—+65.2+96.3+44.9—
Net Income Growth—+26.1+95.3+54.6—
EPS Growth—+41.7+67.6+42.1—
Total Assets Growth—+7.1+2.1+29.2—
Total Equity Growth—+12.5+18.7+21.3—
Cash from Operations Growth—-156.6+493.3+147.8—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.